Chemotherapy, immunity and microbiota--a new triumvirate?
- PMID: 24504404
- PMCID: PMC4339017
- DOI: 10.1038/nm.3473
Chemotherapy, immunity and microbiota--a new triumvirate?
Abstract
The growing relevance of the gut microbiota to various human diseases may also directly impinge on the efficacy of chemotherapeutics. A recent study shows that subcutaneous tumors fail to respond to immunotherapy and platinum chemotherapy after antibiotic treatment, whereas another study reports that the effect of cyclophosphamide on the antitumor immune response relies on the presence of a ‘healthy’ gut microbiota. The mechanisms mediating the role of the microbiota in the immune system during chemotherapy seem to involve the innate and adaptive immune arms. The unexpected influence of commensal intestinal bacteria in the outcome of cancer treatment and the function of anticancer immunity poses new questions from a preclinical and clinical standpoint in the cancer field.
Comment on
-
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.Science. 2013 Nov 22;342(6161):967-70. doi: 10.1126/science.1240527. Science. 2013. PMID: 24264989 Free PMC article.
-
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537. Science. 2013. PMID: 24264990 Free PMC article.
References
-
- Tosolini M, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (TH1, TH2, Treg, TH17) in patients with colorectal cancer. Cancer Res. 2011;71:1263–1271. - PubMed
-
- Chung AS, et al. An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013;19:1114–1123. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources